Research Explorer

Project

A novel CRISPR/Cas9-based nanomedicine strategy targeting CD4+ cells to cure HIV
Code
01D02522
Duration
01 October 2022 → 31 October 2022
Funding
Regional and community funding: Special Research Fund
Research disciplines
  • Medical and health sciences
    • Virology
    • Biopharmaceuticals
    • Pharmaceutical technology
    • Infectious diseases
  • Engineering and technology
    • Nanomaterials
Keywords
HIV lipid nanoparticles CRISPR/Cas9
 
Project description
 

In this proposal, we aim to design lipid nanoparticles coated with anti-CD4 nanobodies that encode CRISPR/Cas9 ribonucleoproteins targeting both ends of the HIV genome and the viral coreceptor CCR5. As such, our novel nanomedicine will selectively purge HIV reservoirs in CD4+ cells, while conferring healthy CD4+ cells resistant to HIV reinfection, and off-target effects in non-target cells will remain minimal.